Mark D. Matteucci
Plus aucun poste en cours
Historique de carrière de Mark D. Matteucci
Anciens postes connus de Mark D. Matteucci
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/01/1988 | 01/01/1999 |
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Directeur Technique/Scientifique/R&D | 01/08/2002 | - |
| Corporate Officer/Principal | 01/08/2002 | - |
Formation de Mark D. Matteucci
| Massachusetts Institute of Technology | Undergraduate Degree |
| The University of Colorado | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Finance | 2 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
- Bourse
- Insiders
- Mark D. Matteucci
- Expérience
